Spots Global Cancer Trial Database for stage iv cutaneous melanoma

Every month we try and update this database with for stage iv cutaneous melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting	NCT05079113	Stage III Melan... Stage IV Cutane...		18 Years -	Case Comprehensive Cancer Center
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	NCT02587650	ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib	18 Years -	University of California, San Francisco
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies	NCT03590054	Stage III Cutan... Stage IV Cutane... Locally Advance... Locally Advance... Metastatic Head... Metastatic Mali... Metastatic Mela... Metastatic Urot... Non-Small Cell ... Stage IB Lung C... Stage III Cutan... Stage III Lung ... Stage III Urete... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Cutane... Stage IV Lung C... Stage IV Ureter... Stage IVA Lung ... Stage IVB Lung ...	Abexinostat Pembrolizumab	18 Years -	University of California, San Francisco
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	NCT02587650	ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib	18 Years -	University of California, San Francisco
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting	NCT05079113	Stage III Melan... Stage IV Cutane...		18 Years -	Case Comprehensive Cancer Center
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	NCT02587650	ALK Fusion Prot... BRAF wt Allele Invasive Skin M... MET Fusion Gene... NRAS wt Allele NTRK1 Fusion Po... NTRK2 Fusion Po... NTRK3 Fusion Po... RET Fusion Posi... ROS1 Fusion Pos... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Capmatinib Ceritinib Entrectinib Laboratory Biom... Regorafenib	18 Years -	University of California, San Francisco

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: